Peristomal Pyoderma Gangrenosum Responding to Risankizumab.
Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve complete remission in only 50% of patients an...
| Publicado en: | Advances in Skin & Wound Care Vol. 34; no. 6; pp. 327 - 330 |
|---|---|
| Autores principales: | , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Jun2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |